Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...

A study in the journal The Lancet found that early-onset colorectal cancer incidence rates are rising in 27 of 50 countries ...

The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s ...

Johnson & Johnson (NYSE: JNJ) has announced important overall survival (OS) results from the Phase III MARIPOSA study.

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Colorectal cancer can be influenced by both genetics and lifestyle. Parkway Cancer Center oncologist Dr. Zee Ying Kiat shares ...

Stan Lee and Jack Kirby gave the X-Men franchise its most enduring heroes and villains - but some creations don't get the ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent ...

A study published March 27 in the journal Science finds that a unique and ancient spate of genetic mutations was key to the ...

Jamie Oliver’s take on a classic Valencian dish maybe deliciously tasty but it is not paella - here is the crucial reason why ...